Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01806935
Other study ID # 2012-A01547-36
Secondary ID
Status Completed
Phase N/A
First received March 6, 2013
Last updated September 25, 2013
Start date April 2013
Est. completion date September 2013

Study information

Verified date February 2013
Source Pierre Fabre Medicament
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the the effect of the study product on itching symptoms associated with xerotic dermatitis in aged population


Recruitment information / eligibility

Status Completed
Enrollment 442
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 70 Years and older
Eligibility Inclusion Criteria:

- Aged from 70 years

- With xerotic dermatitis, clinically assessed ,

- At least on the anterior part of lower and/or upper limbs,

- Presenting itching xerotic dermatitis evolving from at least 3 weeks

- Intensity of itching = 4 on VAS (0-10) at th inclusion time

- With MMSE score = 20 dating less than 6 months

- Affiliated to a social security system, or is a beneficiary (as applicable in the national regulation)

Exclusion Criteria:

- Criteria related to pathologies

- Severe form of other dermatitis requiring either systemic treatment

-- Itching xerotic dermatitis from iatrogenic origins

- Dermatological disease other than xerotic dermatitis which could interfere with the assessment,

- Systemic disease that may generate xerotic dermatitis and /or pruritus

- Immunosuppression condition,

- History of serious disease considered by the investigator hazardous for the patient or incompatible with the study.

- Criteria related to treatment

- Use of treatment which could interfere with the evaluation of the disease or the course of the disease

- Criteria related to the population

- Ongoing participation to another clinical trial or participation in the previous month before the inclusion

- Patient under guardianship or trusteeship

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
DC086

Placebo


Locations

Country Name City State
France 0521 Angers
France 0523 Angers
France 0520 Cugnaux
France 0517 Le Fousseret
France 0518 Muret
France 0519 Muret
France 0515 Saint Orens de Gameville
France 0516 Saint Orens de Gameville
France 0511 Seysses
France 0512 Seysses
France 0513 Seysses
France 0514 Seysses
France 0522 Tierce
France 0501 Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Pierre Fabre Medical Devices

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Itching symptoms intensity change From Day 1 to 28 days No